Publication
Outcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients.
Supavich Tannumsaeng, Usanarat Anurathapan, Arpatsorn Sermcheep, Pattara Kanjanakan, Chayamon Takpradit, Kleebsabai Sanpakit, Pimjai Niparuck, Thanakrit Piyajaroenkij, Adisak Tantiworawit, Korakot Atjanasuppat, Piamsiri Sawaisorn, Sarinthip Preedagasamzin, Bunyada Jittorntrum, Somsak Prasongtanakij, Samart Pakakasama, Suradej Hongeng
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Donor-derived anti-CD19 chimeric antigen receptor T-cell (CAR T-cell) therapy has emerged as one of the most promising treatments for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). In this retrospective study, we evaluated the safety and efficacy of donor-derived anti-CD19…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerLeukemiadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available